Related Experiment Video
Updated: Feb 15, 2026
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
Predicting mucosal healing in patients with ulcerative colitis in clinical remission using biomarkers: A
Naohiro Kato1, Ryusaku Kusunoki2, Hiroki Kamada1
1Department of Endoscopy, NHO Kure Medical Center and Chugoku Cancer Center, Kure, Japan.
Abstract:
Treating ulcerative colitis (UC) requires mucosal healing (MH); however, clinical remission does not always involve MH. Fecal calprotectin (FC) is a useful marker to determine MH. Leucine-rich alpha-2 glycoprotein (LRG) and prostaglandin E-major urinary metabolite (PGE-MUM) have similar performance to FC and may also predict MH. No previous studies have provided a detailed comparative analysis of LRG, PGE-MUM, and FC. Herein, we investigated their associations with endoscopic activity and their potentials as predictors of MH. This single-center, prospective, observational study included patients with ulcerative colitis in clinical remission for >3 months (partial Mayo score ≤ 2) who were to undergo colonoscopy between July 2023 and June 2024. Endoscopic remission (ER) was defined as Mayo endoscopic score of 0, while histological remission (HR) was based on the Geboes score. Overall, 46 patients were enrolled, and all underwent colonoscopy; 20 (43%) had ER, and 9 (20%) had HR. The median LRG, PGE-MUM, and FC levels were significantly higher in patients without ER than in those who achieved ER (P < .05). The areas under the receiver operating characteristic curves of LRG, PGE-MUM, and FC for determining ER were 0.686 (95% confidence interval [CI]: 0.530-0.845), 0.695 (95% CI: 0.552-0.872), and 0.788 (95% CI: 0.658-0.919), respectively. The optimal cutoff value obtained from the receiver operating characteristic curve, LRG, PGE-MUM, and FC values for determining ER were 14.2 µg/mL, 30.6 μg/gCr, and 143 mg/kg, respectively. The areas under the receiver operating characteristic curves for LRG + FC and PGE-MUM + FC to determine ER were 0.800 (95% CI: 0.672-0.928) and 0.865 (95% CI: 0.764-0.966), respectively. LRG and PGE-MUM are potential biomarkers for determining ER in clinical remission. Combining LRG and PGE-MUM assessments with FC may improve the accuracy of confirming ER in ulcerative colitis, even during the remission phase.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:13Patient-centered Care
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...